Seminars in Oncology

Papers
(The H4-Index of Seminars in Oncology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer83
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review73
Masthead44
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer40
Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance34
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment27
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis25
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis22
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance21
Table of Contents20
Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study18
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans18
Role of neoadjuvant pembrolizumab in advanced melanoma16
Editorial Board16
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics15
0.10725498199463